Karyopharm Therapeutics (KPTI) Price to Sales (2013 - 2026)

Karyopharm Therapeutics (KPTI) has reported Price to Sales for 14 consecutive years, with 8.46 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 760.66% year-over-year to 8.46; the trailing twelve-month figure through Jun 2026 stood at 1.89 (up 596.62% YoY), and the FY2025 full-year result was 0.55, down 6.2% from the prior year.
• Price to Sales grew to 8.46 in Q2 2026 per KPTI's latest filing, from 2.36 in the prior quarter.
• Across five years, Price to Sales topped out at 12.28 in Q1 2022 and bottomed at 0.98 in Q2 2025.
• Historically, Price to Sales has averaged 5.5 across 5 years, with a median of 4.26 in 2023.
• The sharpest annual moves came in 2025 and 2026: Price to Sales tumbled 79.89% in 2025, then jumped 760.66% in 2026.
• Over 5 years, Price to Sales stood at 8.29 in 2022, then sank by 64.45% to 2.95 in 2023, then declined by 5.2% to 2.79 in 2024, then fell by 15.46% to 2.36 in 2025, then surged by 258.09% to 8.46 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 8.46, 2.36, and 1.29 for Q2 2026, Q4 2025, and Q3 2025 respectively.